Literature DB >> 35870013

Clinical characteristics and long-term outcomes of rhabdomyosarcoma in Korean children, adolescents and young adults: a single-center experience.

Meerim Park1, Jun Ah Lee1, Hye Young Jin1, Joo-Young Kim2, Jong Woong Park3, June Hyuk Kim3, Hyun Guy Kang3, Seog Yun Park4, Eun Young Park5, Hyeon Jin Park1, Byung Kiu Park6,7.   

Abstract

PURPOSE: This study aimed to analyze characteristics, treatment, long-term outcomes, and prognostic factors for children, adolescents and young adults with rhabdomysosarcoma (RMS).
METHODS: This retrospective historical study included 75 patients with RMS treated between 2002 and 2019. Clinical data and follow-up results were collected including all diagnosis, treatment and prognosis information.
RESULTS: Patients median-age-at-diagnosis was 6 years. Embryonal and alveolar histology occurred in 51 (68.0%) and 21 (28.0%) patients, respectively. The tumors most frequently originated from parameningeal site (28.0%). Of 74 evaluable patients for treatment outcome, 60 (81.1%) achieved complete response for first-line treatment, of whom, 34 (56.6%) maintained complete response, 26 (43.3%; 23/26, local relapse) showed relapse. Of 40 patients with treatment failure, 16 and 6 occurred in parameningeal area and retroperitoneum/perineum, respectively. The 5-year progression-free survival (PFS) and overall survival (OS) were 45.0% and 64.5%, respectively. In multivariate analyses, parameningeal site (p = 0.027), no gross total resection (p = 0.047), and no radiation therapy (RT) (p < 0.001) for PFS; and parameningeal site (p < 0.001) and no RT (p = 0.010) for worse OS, were significant. The median PFS and OS from treatment failure date in 40 patients with primary treatment failure were 1.3 and 4.1 years, respectively. Of 26 patients with relapse, interval to relapse < 7 months, retroperitoneum/perineum site, TNM stages III/IIV, and no salvage RT were independently associated with OS.
CONCLUSION: The importance of adequate local therapy was highlighted in RMS treatment. Treatment failure was largely a local failure. Whether as a component of initial or salvage treatment, RT could improve patients' survival.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Local control; Parameningeal; Prognosis; Rhabdomyosarcoma

Year:  2022        PMID: 35870013     DOI: 10.1007/s00432-022-04192-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  29 in total

Review 1.  Common solid tumors of childhood.

Authors:  W M Crist; L E Kun
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

2.  Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Gianni Bisogno; Gian Luca De Salvo; Christophe Bergeron; Soledad Gallego Melcón; Johannes H Merks; Anna Kelsey; Helene Martelli; Veronique Minard-Colin; Daniel Orbach; Heidi Glosli; Julia Chisholm; Michela Casanova; Ilaria Zanetti; Christine Devalck; Myriam Ben-Arush; Peter Mudry; Sima Ferman; Meriel Jenney; Andrea Ferrari
Journal:  Lancet Oncol       Date:  2019-09-24       Impact factor: 41.316

3.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.

Authors:  W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

Review 4.  Consensus and controversies regarding the treatment of rhabdomyosarcoma.

Authors:  Scott C Borinstein; Diana Steppan; Masanori Hayashi; David M Loeb; Michael S Isakoff; Odion Binitie; Andrew S Brohl; Julia A Bridge; Mark Stavas; Eric T Shinohara; William H Meyer; Damon R Reed; Lars M Wagner
Journal:  Pediatr Blood Cancer       Date:  2017-09-14       Impact factor: 3.167

Review 5.  Oral radiation-induced sarcomas: Systematic review.

Authors:  Lucas L de Souza; Hélder A R Pontes; Alan R Santos-Silva; Lais A Fernandes; Luana A L Batista; Márcio A Lopes; Waqas Khan; Flávia S C Pontes
Journal:  Head Neck       Date:  2020-04-28       Impact factor: 3.147

6.  Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma.

Authors:  Tobias M Dantonello; Christoph Int-Veen; Andreas Schuck; Guido Seitz; Ivo Leuschner; Michaela Nathrath; Paul-Gerhardt Schlegel; Udo Kontny; Wolfgang Behnisch; Iris Veit-Friedrich; Stefanie Kube; Erika Hallmen; Bernarda Kazanowska; Ruth Ladenstein; Michael Paulussen; Gustaf Ljungman; Stefan S Bielack; T Klingebiel; E Koscielniak
Journal:  Pediatr Blood Cancer       Date:  2013-02-15       Impact factor: 3.167

7.  An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Population-Based Evidence for a Cancer Predisposition Syndrome?

Authors:  Natasha M Archer; Renata Parada Amorim; Rafaela Naves; Simone Hettmer; Lisa R Diller; Karina Braga Ribeiro; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2015-07-20       Impact factor: 3.167

8.  Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma.

Authors:  S C Clement; R A Schoot; O Slater; J C Chisholm; C Abela; A J M Balm; M W van den Brekel; W B Breunis; Y C Chang; R Davila Fajardo; D Dunaway; E Gajdosova; M N Gaze; S Gupta; B Hartley; L C M Kremer; M van Lennep; G A Levitt; H C Mandeville; B R Pieters; P Saeed; L E Smeele; S D Strackee; C M Ronckers; H N Caron; H M van Santen; J H M Merks
Journal:  Eur J Cancer       Date:  2015-12-17       Impact factor: 9.162

Review 9.  Current and Future Treatment Strategies for Rhabdomyosarcoma.

Authors:  Celine Chen; Heathcliff Dorado Garcia; Monika Scheer; Anton G Henssen
Journal:  Front Oncol       Date:  2019-12-20       Impact factor: 6.244

10.  The Impact of Radiation Therapy in Children and Adolescents With Metastatic Rhabdomyosarcoma.

Authors:  Alison L Cameron; Markus C Elze; Michela Casanova; Birgit Geoerger; Mark N Gaze; Veronique Minard-Colin; Kieran McHugh; Rick R van Rijn; Anna Kelsey; Hélène Martelli; Henry Mandeville; Gianni Bisogno; Stephen Lowis; Milind Ronghe; Daniel Orbach; Cecile Guizani; Sabine Fürst-Recktenwald; Julia C Chisholm; Johannes H M Merks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-07-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.